


正 誤 表

「パートナー生薬学（改訂第4版増補 第1刷）」

下記の箇所に誤りがございました。謹んでお詫びし訂正いたします。

頁	該当箇所	誤	正
33	図3-1	E：カラスビシャクの根茎，F：オニユリの根茎	E：カラスビシャクの塊茎，F：オニユリの鱗茎
45	図3-13	<i>Clematis uncinata</i> Champ. ex Benth. の小葉	<i>Clematis uncinata</i> Champ. ex Benth. の小葉
65	図4-14 Anetholeの構造式	略	<p>図差し替え</p> <p>The diagram illustrates the biosynthetic pathway of anethole and related compounds. It starts with phenylalanine and tyrosine. Phenylalanine is converted to cinnamic acid by the enzyme PAL, and tyrosine is converted to p-coumaric acid by the enzyme TAL. p-coumaric acid is then converted to caffeic acid, ferulic acid, and anethole. Ferulic acid is converted to vanillin, which is further converted to coniferyl alcohol, eugenol, and lignans/lignins. p-coumaric acid is also converted to trans and cis coumarins.</p>

68	<p>図4-18 catechinの構造式</p>	略	<p>図差し替え</p> <p>The diagram illustrates the biosynthetic pathway of catechin. It begins with <i>p</i>-coumaric acid, which is activated to <i>p</i>-coumaroyl-CoA. This intermediate then reacts with three molecules of acetyl-CoA to form a polyketide chain. The chain is cyclized to form flavone, which is further modified to flavanone. Flavanone can be converted to flavonol, chalcone, or catechin. Chalcone can be converted to stilbene or isocoumarin. Catechin can be converted to cyanidin.</p>
147	coclaurineの構造式	略	<p>図差し替え</p> <p>The structure shows coclaurine, a tetracyclic alkaloid. It features a piperidine ring fused to a benzene ring, which is further fused to a quaternary carbon atom bonded to a piperidine ring and a phenethylamine moiety. The structure includes a methoxy group (CH₃O) and a hydroxyl group (HO) on the benzene ring, and another hydroxyl group (HO) on the phenethylamine moiety.</p>
150	<p>性状 2行目 成分 1行目</p>	ケイアルデヒド	シンナムアルデヒド

158	aconitine 等の構造式	略	<p>図差し替え</p>  <table data-bbox="1097 478 1523 638"> <thead> <tr> <th></th> <th>R¹</th> <th>R²</th> <th>R³</th> </tr> </thead> <tbody> <tr> <td>aconitine</td> <td>C₂H₅</td> <td>OH</td> <td>COCH₃</td> </tr> <tr> <td>mesaconitine</td> <td>CH₃</td> <td>OH</td> <td>COCH₃</td> </tr> <tr> <td>hypaconitine</td> <td>CH₃</td> <td>H</td> <td>COCH₃</td> </tr> <tr> <td>benzoylmesaconine</td> <td>CH₃</td> <td>OH</td> <td>H</td> </tr> </tbody> </table>		R ¹	R ²	R ³	aconitine	C ₂ H ₅	OH	COCH ₃	mesaconitine	CH ₃	OH	COCH ₃	hypaconitine	CH ₃	H	COCH ₃	benzoylmesaconine	CH ₃	OH	H
	R ¹	R ²	R ³																				
aconitine	C ₂ H ₅	OH	COCH ₃																				
mesaconitine	CH ₃	OH	COCH ₃																				
hypaconitine	CH ₃	H	COCH ₃																				
benzoylmesaconine	CH ₃	OH	H																				
189	薬理 9行目	カリウムイオンの排泄を促進し,	カリウムイオンの排泄を促進するため,																				
195	確認試験 3行目	(matrine, oxymatrine) .	(matrine, oxymatrine) (付録p.396参照) .																				
197	確認試験 2行目	(brasilin) .	(brasilin) (付録p.400参照) .																				
372	3行目	コビトジャコウジカ <i>M. berezowskii Flerov</i>	コビトジャコウジカ <i>M. berezovskii Flerov</i>																				
453	世界の生薬生産地図	(中国・朝鮮半島は裏見返しに詳細図あり)	(中国・朝鮮半島はp.450～451に詳細図あり)																				

2024年1月31日
株式会社南江堂